Enhanced Long-Term Care of Severe Respiratory Failure

描述（由申请人提供）：目前对急性呼吸窘迫综合征（ARDS）的治疗效果欠佳。动静脉二氧化碳清除（AVCO2R）结合轻度氧气通气已显示出前景。AVCO2R是一种温和的无泵技术，使用低压降膜式氧合器，可减少劳动力、成本、复杂性和患者压力。虽然AVCO2R的工作时间很短，但ARDS治疗必须连续工作数周。 第一阶段成功地证明了CMS无孔膜显着提高AVCO2R膜的长期抗润湿性，同时保持二氧化碳去除膜组件的流体动力学。 我们与德克萨斯大学（UT）密切合作，使用UT绵羊模型在10只绵羊上完成了短期体内试验。体内结果显示CMS AVCO2R系统与对照相比有利。长期体内测试进一步支持CMS新膜技术。 第二阶段将在第一阶段可行性成功的基础上，首先优化膜组件的制造。与UT合作，我们将进行广泛的体外测试，然后进行大量（40+）长期绵羊研究。 CMS拥有众多工业合作伙伴，可协助第二阶段系统制造和后续评估。这些关系将有助于第二阶段以及确定适当的商业化合作伙伴。

DESCRIPTION (provided by applicant): Current management of acute respiratory distress syndrome (ARDS) is suboptimal. Arteriovenous carbon dioxide removal (AVCO2R) combined with mild oxygen ventilation has shown promise. AVCO2R is mild pumpless technique using low-pressure drop membrane oxygenators, which reduces labor, cost, complexity and patient stress. While AVCO2R works for short durations, ARDS therapy must operate continuously for weeks. Phase I successfully demonstrated CMS non-porous membranes significantly enhance AVCO2R membrane long term wet-out resistance while maintaining carbon dioxide removal membrane modules fluid dynamics. Working closely with University of Texas (UT) we completed short-term in-vivo testing on 10 sheep using UT sheep model. In-vivo results showed CMS AVCO2R system compared favorably to control. Long term in-vivo testing further supported CMS new membrane technology. Phase II will build upon Phase I feasibility success and first optimize membrane module fabrication. Working with UT we will do extensive in-vitro testing and then perform numerous (40+) long-term sheep studies. CMS has numerous industrial partners assisting in Phase II system fabrication and subsequent evaluation. These relationships will help Phase II plus identifying appropriate commercialization partners.